Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)
A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)
Sponsor: Novo Nordisk A/S
This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 2 and is currently completed. Novo Nordisk A/S leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark , Aberdeen, United Kingdom , Aguascalientes, Mexico , Albany, United States , Almería, Spain , Anaheim, United States , Ankara, Turkey (Türkiye) , Annaba, Algeria , Antalya, Turkey (Türkiye) , Antequera, Spain and 208 more locations